ArticleCureus2025
Association Between Calcium Phosphate Product and Carotid Intimal Medial Thickness in Patients With Chronic Kidney Disease: A Cross-Sectional Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Chronic kidney disease has been found to increase the risk of cardiovascular disease (CVD). Carotid intima media thickness (CIMT) is a commonly used surrogate marker for assessing atherosclerosis. Recent interest has emerged in exploring the potential of calcium phosphate product (Ca x Pi) as an alternative or adjunct in evaluating cardiovascular risk in these patients. This study aimed to find the correlation between Ca x Pi and CIMT in patients with advanced chronic kidney disease. Methods A cross-sectional study was conducted at Thumbay Hospital New Life, Hyderabad, from January 2020 to December 2020. Fifty patients with advanced chronic kidney disease (stages 3 and above) were included after applying the inclusion and exclusion criteria. Serum Ca x Pi levels were measured along with CIMT using carotid ultrasound. Statistical analysis was performed to assess the correlation between Ca x Pi and CIMT. Results The mean Ca x Pi was 44.8±11, and the mean CIMT was 1.68±0.47 mm. A positive correlation was found between Ca x Pi and CIMT (p = 0.03), while serum phosphorus showed a strong correlation with CIMT (p < 0.01). Conclusion Ca x Pi shows promise as a surrogate marker for assessing cardiovascular risk in patients with chronic kidney disease, alongside CIMT. Further research, including larger longitudinal studies, is warranted to validate these findings and explore the utility of Ca x Pi in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.